Market Overview

UPDATE: Goldman Sachs Upgrades Johnson & Johnson Based on Solid Pharma Business


In a report published Friday, Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (NYSE: JNJ) from Sell to Neutral and raised the 12 month PT from $87 to $95.

Rubin noted Johnson and Johnson's solid pharma business performance this year, commenting on launches of Xarelto, Invokana, and Zytiga, as well as the impending launches of Ibrutinib and Simeprevir. The analyst stated, “No company depicts this transformation better than JNJ's pharma business, in our view. With 70% of current sales leveraged to specialty/biologics and with most of JNJ's pipeline assets following the same pattern, we expect product mix to continue moving closer to biotech.”

The analyst reminded investors that although JNJ has been a strong stock (up 26% versus S&P 500 +15%, S&P Healthcare +23% and S&P Pharma +15%), it has fallen behind the group since late summer. Rubin continues to see limits of value creation due to Johnson and Johnson's current diversified structure.

Goldman Sachs estimated 3Q EPS of $1.32 and 2013 EPS of $5.48, a slight upward revision based on new product launches. JNJ closed at $85.96 on Thursday and is currently trading up 2.12% this morning.


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: Goldman Sachs Jami RubinAnalyst Color Upgrades Analyst Ratings

Latest Ratings

TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at